Navigation Links
Dermaseptins: Potent vaginal contraceptives

Safe and effective vaginal contraceptives are urgently needed. Ideally, such products should have antimicrobial and antiviral properties; as such, they could also play a role in the reduction of sexually// transmitted diseases (STDs), particularly the human immunodeficiency virus (HIV).

Most of the spermicidal products being marketed presently contain a detergent as an active ingredient, which do not provide any protection against STDs and that their effect in preventing HIV transmission remains controversial. Also, the repeated use of a surfactant as a vaginal contraceptive/microbicide has been associated with an increased risk of vaginal or cervical infection and irritation or ulceration. Because of this, it is important to identify and evaluate a new generation of contraceptive antimicrobial agents can be used vaginally in effective doses without causing overt vaginal irritation or other toxicity.

Antimicrobial peptides are produced by both prokaryotic and eukaryotic cells and have been the subject of many studies in recent years because of their involvement in host defense mechanisms and their potential use as therapeutic agents. These antimicrobial peptides include dermaseptins (DSs), a family of five structurally and functionally related peptides that were originally isolated from the skin of a tree-dwelling South American frog (Phyllomedusa sauvagei).

Recently, researchers from the Laboratory of Biochemistry, Faculty of Medicine, Sousse, Tunisia, thought that it would be interesting to develop a vaginal contraceptive with these compounds that have many biologic properties.

In their study, to be published in Contraception (available online 26 August 2005), the researchers set out to determine the effectiveness of two synthetic antimicrobial peptides, dermaseptin (DS1 and DS4) for inhibiting sperm motility. In addition, the mechanism of their spermicidal action was investigated and possible synergistic spermicidal effects exerted by EDTA were evaluated.

For the study, twenty samples of fresh semen were obtained from patients aged between 23 and 35 years. The data showed that sperm motility was inhibited with various concentrations of DS at different intervals ranging from 2 to 240 min. The action of DSs on sperm motility was observed to be dose dependent. Supplementation with pentoxifylline and that with calcium are known to enhance the motility of sperm but they did not prevent the spermicidal action of DSs.

This study indicates that DS is an effective agent to kill sperm. In view of this fact, it is suggested that DS4 has antibacterial, antiviral, antifungal and potentially spermicidal activities and could be a potent vaginal contraceptive.

However, the authors state that further studies are necessary to elucidate the mode of DS action, and suggest that considering the available information about contraceptive efficacy, the different biologic properties of these peptides should be studied as new candidates for human use as a barrier contraceptive agent with additional protection against STDs.
'"/>




Related medicine news :

1. Potential New Cancer Gene Identified
2. Lack of Smell And Its Potential Risks
3. New Blood Thinner Pill - First Potential Alternative to Warfarin in 50 years
4. The Potential Of Cadaver Transplantation Programme In India
5. Another Potential Of Stem Cells Discovered: Used For Growing Cartilage
6. Yoga Guru Ramdev Invited to Tap Ayurveda Potential by Jharkhand Govt
7. A Protein In Yoghurt Has The Potential To Fight E. coli
8. Gold Therapy- A Potential Treatment For Autoimmune Diseases
9. Whirlpool Bath Tubs Contain Potentially Lethal Bacterial Strains
10. A Potent Sedative Kills Great-grandfather
11. Potential Benefits Of New Nanotechnology
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology: